Erenumab in the prevention of high‐frequency episodic and chronic migraine: Erenumab in Real Life in Italy (EARLY), the first Italian multicenter, prospective real‐life study — Piero Barbanti (2020) | RDL Network
Erenumab in the prevention of high‐frequency episodic and chronic migraine: Erenumab in Real Life in Italy (EARLY), the first Italian multicenter, prospective real‐life study
Article 2020 en
Authors
PB
Piero Barbanti
CA
Cinzia Aurilia
GE
Gabriella Egeo
Abstract
1 min read
Erenumab 70 mg is effective, safe, and well tolerated in real life. Easily obtainable clinical features might be of help in predicting patient's responsiveness.
Luisa Fofi, Gabriella Egeo, Cinzia Aurilia, Carmelina Maria Costa, Claudia Altamura, Fabrizio Vernieri, Maria Albanese, Florindo d’Onofrio, Laura Di Clemente, Maurizio Zucco, Paola Di Fiore, Fabio Frediani, Roberta Messina, Bruno Colombo, Massimo Filippi, Francesco Bono, Lucia Manzo, Antonio Carnevale, Piero Barbanti, Stefania Proietti, Stefano Bonassi
Discussion(0)
No comments yet. Be the first to comment.